Is Amgen (AMGN) Stock Fairly Valued?

An in-depth analysis of Amgen's valuation, financial strength, profitability, and growth

Article's Main Image

Amgen Inc (AMGN, Financial) experienced a daily gain of 1.56%, with a three-month gain of 13.96%. The company's Earnings Per Share (EPS) (EPS) stands at 14.83. The question we aim to answer: Is Amgen (AMGN) fairly valued?

Read on for a comprehensive valuation analysis of Amgen, which will provide insights into whether the stock is overvalued, undervalued, or rightly priced.

Company Overview

Amgen is a pioneer in biotechnology-based human therapeutics, with a rich history in renal disease and cancer supportive-care products. The company's flagship drugs include Epogen, Aranesp, Neupogen, Neulasta, Enbrel, and Otezla. Amgen's stock price currently stands at $265.05, with a market cap of $141.80 billion.


Understanding GF Value

The GF Value represents the intrinsic value of a stock, derived from a unique methodology. It considers historical trading multiples, GuruFocus adjustment factor based on past performance and growth, and future business performance estimates.

At its current price of $265.05 per share and the market cap of $141.80 billion, Amgen stock is believed to be fairly valued. This suggests that the long-term return of its stock is likely to be close to the rate of its business growth.


Financial Strength

Understanding the financial strength of a company is crucial before investing. Amgen has a cash-to-debt ratio of 0.56, which is worse than 58.82% of companies in the Drug Manufacturers industry. The overall financial strength of Amgen is 5 out of 10, indicating fair financial health.


Profitability and Growth

Investing in profitable companies, especially those with consistent profitability over the long term, is less risky. Amgen has been profitable 10 over the past 10 years. Its operating margin is 35.72%, which ranks better than 97.3% of companies in the Drug Manufacturers industry.

One of the most important factors in the valuation of a company is growth. The average annual revenue growth of Amgen is 8.2%, which ranks better than 57.11% of companies in the Drug Manufacturers industry. However, the 3-year average EBITDA growth is 2.7%, which ranks worse than 62.42% of companies in the same industry.


Comparing a company's return on invested capital (ROIC) to its weighted cost of capital (WACC) is another way to evaluate its profitability. Over the past 12 months, Amgen's ROIC was 18.89, while its WACC came in at 7.07.



In conclusion, Amgen (AMGN, Financial) stock is believed to be fairly valued. The company's financial condition is fair, and its profitability is strong. Its growth ranks worse than 62.42% of companies in the Drug Manufacturers industry. To learn more about Amgen stock, you can check out its 30-Year Financials here.

To find out the high quality companies that may deliver above average returns, please check out GuruFocus High Quality Low Capex Screener.


I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours. Click for the complete disclosure